Khaled Ghanem
Research Subjects
Khaled Ghanem has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
Nidale Tarek
Children\'s Cancer Center of Lebanon
3 shared publicationsRaya Saab
American University of Beirut Medical Center
3 shared publications- Carlos Rodriguez-Galindo
Department of Global Pediatric Medicine St. Jude Children's Research Hospital Memphis Tennessee USA
2 shared publications Hani Tamim
American University of Beirut
2 shared publicationsMiguel R. Abboud
Department of Pediatrics and Adolescent Medicine, Hematology Oncology Service, Children's Cancer Center of Lebanon, American University of Beirut, Beirut, Lebanon
2 shared publicationsRami Mahfouz
American University of Beirut Medical Center
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (9)
Crossing Borders for Pathology Capacity Building in a Regional Setting: A Pediatric Oncology Initiative
PURPOSE: Barriers to accurate histopathologic diagnosis in lower middle-income countries (LMIC) undermine appropriate patient outcomes. We report the results of a regional LMIC twinning initiative, with the support of a high-income country institution, for building capacity in histopathologic diagnosis of pediatric cancers. METHODS: A pathology review initiative was conducted between July 2019 and June 2024, where 6 cases per month from a developing center in Syria were reviewed regionally at an established center in Lebanon. Cases for which no diagnosis could be made were sent to St Jude Children's Research Hospital for a third read. Monthly meetings were held to discuss diagnoses and reasons for discrepancies. Biannual capacity building meetings were held to discuss opportunities for improvement. RESULTS: A total of 81 cases were reviewed, of which 44 were extracranial solid tumors, 29 brain tumors, and eight hematologic malignancies. Of these, 77 were of sufficient quality, and seven were sent for a third read. Among the 70 cases with a regional final diagnosis, 53 (76%) were concordant, 12 (17%) had major discrepancies, and 5 (7%) had minor discrepancies. Reasons for discrepancies were morphologic interpretation (n = 9, 52%), combined interpretation and immunohistochemistry (n = 4, 24%), and unavailability of specific immunostains (n = 4, 24%). The highest number of discrepancies were in brain tumors, followed by solid tumors. Several opportunities were identified for local improvement and patient safety, including focused pathologist training and specific assay development. CONCLUSION: Our results demonstrate the feasibility of a supported regional south-south twinning initiative in building capacity for accurate pediatric oncology histopathology. Beyond knowledge transfer, it revealed areas for local improvement including specific local laboratory processes, technical training, and local reporting tools.
- 1 September 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (9)
Open AccessCrossing Borders for Pathology Capacity Building in a Regional Setting: A Pediatric Oncology Initiative
PURPOSE: Barriers to accurate histopathologic diagnosis in lower middle-income countries (LMIC) undermine appropriate patient outcomes. We report the results of a regional LMIC twinning initiative, with the support of a high-income country institution, for building capacity in histopathologic diagnosis of pediatric cancers. METHODS: A pathology review initiative was conducted between July 2019 and June 2024, where 6 cases per month from a developing center in Syria were reviewed regionally at an established center in Lebanon. Cases for which no diagnosis could be made were sent to St Jude Children's Research Hospital for a third read. Monthly meetings were held to discuss diagnoses and reasons for discrepancies. Biannual capacity building meetings were held to discuss opportunities for improvement. RESULTS: A total of 81 cases were reviewed, of which 44 were extracranial solid tumors, 29 brain tumors, and eight hematologic malignancies. Of these, 77 were of sufficient quality, and seven were sent for a third read. Among the 70 cases with a regional final diagnosis, 53 (76%) were concordant, 12 (17%) had major discrepancies, and 5 (7%) had minor discrepancies. Reasons for discrepancies were morphologic interpretation (n = 9, 52%), combined interpretation and immunohistochemistry (n = 4, 24%), and unavailability of specific immunostains (n = 4, 24%). The highest number of discrepancies were in brain tumors, followed by solid tumors. Several opportunities were identified for local improvement and patient safety, including focused pathologist training and specific assay development. CONCLUSION: Our results demonstrate the feasibility of a supported regional south-south twinning initiative in building capacity for accurate pediatric oncology histopathology. Beyond knowledge transfer, it revealed areas for local improvement including specific local laboratory processes, technical training, and local reporting tools.
- Open Access
- 9 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (4) , 1575-1580
Primary Ewing Sarcoma of the urinary bladder in an adolescent: a case report of successful organ preservation with multimodal therapy
Introduction and importance: Primary bladder sarcomas, particularly Ewing Sarcoma/primitive neuroectodermal tumor (ES/PNET), are exceptionally rare in the pediatric and adolescent population, presenting diagnostic and therapeutic challenges. Case presentation: A 15-year-old Syrian girl from a rural area, presented with lower abdominal pain and gross hematuria. Examination revealed suprapubic tenderness. Computed tomography identified a bladder dome mass and a subsequent image-guided biopsy confirmed ES/PNET. The patient received eight cycles of neoadjuvant chemotherapy, which led to significant regression on post-chemotherapy magnetic resonance imaging. Partial cystectomy with 2-cm margins was performed, followed by primary bladder closure. Pathology confirmed pathological complete response, showing no viable tumor (inflammatory changes, urothelial hyperplasia, necrosis, and fibrosis). Adjuvant radiotherapy was administered, and the patient is currently completing adjuvant chemotherapy. Surveillance imaging and cystoscopy 2 months post-operatively showed no evidence of recurrent disease. Clinical discussion: The rarity of bladder ES/PNET presents a therapeutic challenge. This case aligns with emerging evidence that neoadjuvant chemotherapy can be highly effective, facilitating less radical surgery. This strategy successfully avoided radical cystectomy, thereby preventing the associated long-term complications of urinary diversion. The addition of adjuvant radiotherapy was motivated by the initial presence of extensive soft tissue invasion and borderline lymph nodes, aiming to optimize local control. Conclusion: Multimodal therapy with neoadjuvant chemotherapy followed by adjuvant chemotherapy and radiotherapy can facilitate bladder preservation in pediatric bladder ES/PNET without compromising oncological outcomes. This strategy can mitigate the long-term morbidity of radical surgery.
- 9 March 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (4) , 1575-1580
Open AccessPrimary Ewing Sarcoma of the urinary bladder in an adolescent: a case report of successful organ preservation with multimodal therapy
Introduction and importance: Primary bladder sarcomas, particularly Ewing Sarcoma/primitive neuroectodermal tumor (ES/PNET), are exceptionally rare in the pediatric and adolescent population, presenting diagnostic and therapeutic challenges. Case presentation: A 15-year-old Syrian girl from a rural area, presented with lower abdominal pain and gross hematuria. Examination revealed suprapubic tenderness. Computed tomography identified a bladder dome mass and a subsequent image-guided biopsy confirmed ES/PNET. The patient received eight cycles of neoadjuvant chemotherapy, which led to significant regression on post-chemotherapy magnetic resonance imaging. Partial cystectomy with 2-cm margins was performed, followed by primary bladder closure. Pathology confirmed pathological complete response, showing no viable tumor (inflammatory changes, urothelial hyperplasia, necrosis, and fibrosis). Adjuvant radiotherapy was administered, and the patient is currently completing adjuvant chemotherapy. Surveillance imaging and cystoscopy 2 months post-operatively showed no evidence of recurrent disease. Clinical discussion: The rarity of bladder ES/PNET presents a therapeutic challenge. This case aligns with emerging evidence that neoadjuvant chemotherapy can be highly effective, facilitating less radical surgery. This strategy successfully avoided radical cystectomy, thereby preventing the associated long-term complications of urinary diversion. The addition of adjuvant radiotherapy was motivated by the initial presence of extensive soft tissue invasion and borderline lymph nodes, aiming to optimize local control. Conclusion: Multimodal therapy with neoadjuvant chemotherapy followed by adjuvant chemotherapy and radiotherapy can facilitate bladder preservation in pediatric bladder ES/PNET without compromising oncological outcomes. This strategy can mitigate the long-term morbidity of radical surgery.
- Open Access
- 31 January 2024
- Published by Wiley
Association between NUDT15 rs116855232T/C Genetic Polymorphism and Mercaptopurine Toxicity in Syrian Children with Acute Lymphoblastic Leukemia
Purpose: NUDT15 genetic polymorphism is known to be associated with frequent hematopoietic toxicities during acute lymphoblastic leukemia (ALL) mercaptopurine therapy. The aim of this study is to test this association in a group of Syrian children with ALL, in addition to quantify the prevalence of the corresponding SNP in patient population. Patients and Methods: This is a retrospective study that included all children with acute lymphoblastic leukemia reaching at least 6 months of maintenance therapy between January 2018 and May 2020 at two recruitment sites in Damascus, Syria. The NUDT15 rs116855232 genetic polymorphism was performed and linked to four clinical factors: mercaptopurine dose intensity, early onset leukopenia, hepatotoxicity and therapy interruption. Results: A total of 92 patients were enrolled (63.04% low-risk, 25% intermediate-risk and 11.96% high-risk). The TC genotype was found in 5 patients (5.4%) and the TT genotype was found in 1 patient (1.08%), with the following allele frequency: C=0.961 and T=0.038. The mercaptopurine dose intensity was 81.98%, 65.85% and 4.99% for the genotypes CC, TC and TT respectively (P: 0.0174). A significant association was found between early onset neutropenia and NUDT15 polymorphism (TC or TT), OR: 6.82 (95% CI: 1.22-38.11, P: 0.043). No association was found between NUDT15 polymorphism and therapy interruption or hepatotoxicity. Conclusion: Our study confirms that NUDT15 rs116855232 polymorphism is associated with mercaptopurine hematopoietic toxicity but not with hepatotoxicity or therapy interruption in a population of Syrian children with ALL. The incidence seems to be higher than neighboring countries.
- 31 January 2024
- Published by Wiley
Open AccessAssociation between NUDT15 rs116855232T/C Genetic Polymorphism and Mercaptopurine Toxicity in Syrian Children with Acute Lymphoblastic Leukemia
Purpose: NUDT15 genetic polymorphism is known to be associated with frequent hematopoietic toxicities during acute lymphoblastic leukemia (ALL) mercaptopurine therapy. The aim of this study is to test this association in a group of Syrian children with ALL, in addition to quantify the prevalence of the corresponding SNP in patient population. Patients and Methods: This is a retrospective study that included all children with acute lymphoblastic leukemia reaching at least 6 months of maintenance therapy between January 2018 and May 2020 at two recruitment sites in Damascus, Syria. The NUDT15 rs116855232 genetic polymorphism was performed and linked to four clinical factors: mercaptopurine dose intensity, early onset leukopenia, hepatotoxicity and therapy interruption. Results: A total of 92 patients were enrolled (63.04% low-risk, 25% intermediate-risk and 11.96% high-risk). The TC genotype was found in 5 patients (5.4%) and the TT genotype was found in 1 patient (1.08%), with the following allele frequency: C=0.961 and T=0.038. The mercaptopurine dose intensity was 81.98%, 65.85% and 4.99% for the genotypes CC, TC and TT respectively (P: 0.0174). A significant association was found between early onset neutropenia and NUDT15 polymorphism (TC or TT), OR: 6.82 (95% CI: 1.22-38.11, P: 0.043). No association was found between NUDT15 polymorphism and therapy interruption or hepatotoxicity. Conclusion: Our study confirms that NUDT15 rs116855232 polymorphism is associated with mercaptopurine hematopoietic toxicity but not with hepatotoxicity or therapy interruption in a population of Syrian children with ALL. The incidence seems to be higher than neighboring countries.
- 27 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30838
A regional virtual case discussion forum in pediatric oncology: Experience of the Pediatric Oncology East and Mediterranean Group
Background: The Pediatric Oncology East and Mediterranean (POEM) group that aims to share expertise among pediatric oncology providers across the Middle East, North Africa, and East Asia region initiated a virtual Case Discussion Forum (CDF) in 2013.Methods: Meeting records from September 2013 till June 2021 were reviewed. Detailed minutes were available starting August 2016; case data were analyzed including diagnoses, purpose of presentation and recommendations. A 38‐item survey assessing perception of benefits, challenges, and opportunities of the forum was distributed to members of the POEM group and results analyzed.Results: A total of 140 cases were presented from 14 countries. After August 2016, 67 cases were presented, and those were analyzed regarding reasons for discussion, barriers, and recommendations. Details are presented in this report, and the most common challenges identified were related to histopathologic/molecular diagnosis (24%), imaging interpretation (18%), resource limitations (12%), and surgical difficulties (9%). A survey was distributed to all POEM members in 28 countries, and 76 responded. The main benefit reported was the provision of recommendations regarding treatment and evaluation, while the main challenges reported were time zone difference and workload. Recognized opportunities included conducting regionally relevant research studies based on clinical problems identified during discussions, and setting guidelines for resource‐adapted treatment regimens.Conclusions: The POEM CDF identified areas for multi‐institutional regional studies and led to a twinning project between two centers in the region for improving diagnostic infrastructure. Such forums can identify specific resource limitations in pediatric cancer and direct efforts for targeted capacity building.
- 27 December 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (3) , e30838
A regional virtual case discussion forum in pediatric oncology: Experience of the Pediatric Oncology East and Mediterranean Group
Background: The Pediatric Oncology East and Mediterranean (POEM) group that aims to share expertise among pediatric oncology providers across the Middle East, North Africa, and East Asia region initiated a virtual Case Discussion Forum (CDF) in 2013.Methods: Meeting records from September 2013 till June 2021 were reviewed. Detailed minutes were available starting August 2016; case data were analyzed including diagnoses, purpose of presentation and recommendations. A 38‐item survey assessing perception of benefits, challenges, and opportunities of the forum was distributed to members of the POEM group and results analyzed.Results: A total of 140 cases were presented from 14 countries. After August 2016, 67 cases were presented, and those were analyzed regarding reasons for discussion, barriers, and recommendations. Details are presented in this report, and the most common challenges identified were related to histopathologic/molecular diagnosis (24%), imaging interpretation (18%), resource limitations (12%), and surgical difficulties (9%). A survey was distributed to all POEM members in 28 countries, and 76 responded. The main benefit reported was the provision of recommendations regarding treatment and evaluation, while the main challenges reported were time zone difference and workload. Recognized opportunities included conducting regionally relevant research studies based on clinical problems identified during discussions, and setting guidelines for resource‐adapted treatment regimens.Conclusions: The POEM CDF identified areas for multi‐institutional regional studies and led to a twinning project between two centers in the region for improving diagnostic infrastructure. Such forums can identify specific resource limitations in pediatric cancer and direct efforts for targeted capacity building.
- Open Access
- 2 February 2021
- Published by Wiley
Treatment Induced Cerebral Sinus Venous Thrombosis in Childhood Acute Lymphoblastic Leukemia: New Risk Factors to Consider
Background: Cerebral Sinus Venous Thrombosis (CSVT) is one of many side effects encountered during acute lymphoblastic leukemia (ALL) therapy. Due to the rarity of cases, lack of data, consensus management, no recommendations exist to target the population at risk. Methods: This is a retrospective chart review of 229 consecutive patients diagnosed with ALL and aged 1–21 years, treated at the Children’s Cancer Institute (CCI) between October 2007 and February 2017. Results: The incidence of CSVT was 10.5%. Using univariate analysis, increased risk of CSVT was observed with male gender, age >10 years, T-cell immunophenotype, intermediate/high risk disease, maximum Triglyceride (TG) level of > 615 mg/dL, presence of mediastinal mass, and larger body surface area. With multivariate analysis, the only statistically significant risk factors were maximum TG level, body surface area (BSA), presence of mediastinal mass, and risk stratification (intermediate/high risk). Conclusion: Our study was able to unveil TG level of > 615 mg/dL, mediastinal mass, and a larger body surface area as novel risk factors that have not been previously discussed in the literature.
- 2 February 2021
- Published by Wiley
Open AccessTreatment Induced Cerebral Sinus Venous Thrombosis in Childhood Acute Lymphoblastic Leukemia: New Risk Factors to Consider
Background: Cerebral Sinus Venous Thrombosis (CSVT) is one of many side effects encountered during acute lymphoblastic leukemia (ALL) therapy. Due to the rarity of cases, lack of data, consensus management, no recommendations exist to target the population at risk. Methods: This is a retrospective chart review of 229 consecutive patients diagnosed with ALL and aged 1–21 years, treated at the Children’s Cancer Institute (CCI) between October 2007 and February 2017. Results: The incidence of CSVT was 10.5%. Using univariate analysis, increased risk of CSVT was observed with male gender, age >10 years, T-cell immunophenotype, intermediate/high risk disease, maximum Triglyceride (TG) level of > 615 mg/dL, presence of mediastinal mass, and larger body surface area. With multivariate analysis, the only statistically significant risk factors were maximum TG level, body surface area (BSA), presence of mediastinal mass, and risk stratification (intermediate/high risk). Conclusion: Our study was able to unveil TG level of > 615 mg/dL, mediastinal mass, and a larger body surface area as novel risk factors that have not been previously discussed in the literature.
- 29 June 2017
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (12)
Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management
Background: Cerebral sinus venous thrombosis (CSVT) is a rare but serious complication of childhood acute lymphoblastic leukemia (ALL) therapy. No available consensus exists regarding its risk factors and appropriate management due to the rarity of cases.Procedures: Out of 209 ALL patients aged 1–21 years treated at the Children's Cancer Center of Lebanon between May 2002 and May 2015, 13 developed CSVT during therapy. Patient characteristics, clinical management, and outcomes were studied.Results: The incidence of CSVT was 6.2% (95% confidence interval [CI]: 3.4–10.4). Using univariate analysis, increased risk of CSVT was observed with age >10 years (odds ratio [OR]: 3.56, 95% CI: 1.13–11.2), T‐cell immunophenotype (OR: 4.14, 95% CI: 1.16–14.7), and intermediate/high risk disease (OR: 3.4, 95% CI: 1.03–11.7). The only statistically significant risk factor by multivariate analysis was the treatment as per the intermediate‐/high‐risk protocol (HR: 15.6, 95% CI: 1.43–171.3). Most cases (77%) occurred in the postinduction phases of treatment while receiving a combination of asparaginase and dexamethasone rather than prednisone. Treatment with low molecular weight heparin (LMWH) for a minimum of 3 months and until significant radiological improvement is observed resulted in 100% survival rate. All but one patient had complete neurological recovery.Conclusions: CSVT is an important complication of childhood ALL therapy. Postinduction combined asparaginase and dexamethasone intensive treatment for intermediate‐/high‐risk patients was the most important risk factor. Treatment with LMWH for a minimum of 3 months, and until asparginase therapy is over, with major radiological improvement seems to be effective and feasible.
- 29 June 2017
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (12)
Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management
Background: Cerebral sinus venous thrombosis (CSVT) is a rare but serious complication of childhood acute lymphoblastic leukemia (ALL) therapy. No available consensus exists regarding its risk factors and appropriate management due to the rarity of cases.Procedures: Out of 209 ALL patients aged 1–21 years treated at the Children's Cancer Center of Lebanon between May 2002 and May 2015, 13 developed CSVT during therapy. Patient characteristics, clinical management, and outcomes were studied.Results: The incidence of CSVT was 6.2% (95% confidence interval [CI]: 3.4–10.4). Using univariate analysis, increased risk of CSVT was observed with age >10 years (odds ratio [OR]: 3.56, 95% CI: 1.13–11.2), T‐cell immunophenotype (OR: 4.14, 95% CI: 1.16–14.7), and intermediate/high risk disease (OR: 3.4, 95% CI: 1.03–11.7). The only statistically significant risk factor by multivariate analysis was the treatment as per the intermediate‐/high‐risk protocol (HR: 15.6, 95% CI: 1.43–171.3). Most cases (77%) occurred in the postinduction phases of treatment while receiving a combination of asparaginase and dexamethasone rather than prednisone. Treatment with low molecular weight heparin (LMWH) for a minimum of 3 months and until significant radiological improvement is observed resulted in 100% survival rate. All but one patient had complete neurological recovery.Conclusions: CSVT is an important complication of childhood ALL therapy. Postinduction combined asparaginase and dexamethasone intensive treatment for intermediate‐/high‐risk patients was the most important risk factor. Treatment with LMWH for a minimum of 3 months, and until asparginase therapy is over, with major radiological improvement seems to be effective and feasible.
- 31 August 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (1) , 146-150
NUDT15 and TPMT genetic polymorphisms are related to 6‐mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon
Interindividual variability in thiopurine-related toxicity could not be completely explained by thiopurine S-methyltransferase (TPMT) polymorphisms, as a number of patients who are homozygous wild type or normal for TPMT still develop toxicity that necessitates 6-mercaptopurine (MP) dose reduction or protocol interruption. Recently, few studies reported on an inherited nucleoside diphosphate-linked moiety X motif 15 (NUDT15) c.415C>T low-function variant that is associated with decreased thiopurine metabolism and leukopenia in childhood acute lymphoblastic leukemia (ALL) and other diseases. The aim of this study is to measure the frequency of TPMT and NUDT15 polymorphisms and assess whether they are predictors of MP intolerance in children treated for ALL. One hundred thirty-seven patients with ALL of whom 121 were Lebanese were evaluated. MP dose intensity was calculated as the ratio of the tolerated MP dose to planned dose during continuation phase to maintain an absolute neutrophil count (ANC) dose above 300 per μl. One patient was NUDT15 heterozygous TC and tolerated only 33.33% of the planned MP dose, which was statistically significantly different from the median-tolerated MP dose intensity of the rest of the cohort (76.00%). Three patients had the TPMT*3A haplotype and tolerated 40.00–66.66% of the planned MP dose, which was also statistically significantly different from the rest of the cohort. This is the first report on the association of TPMT and NUDT15 polymorphisms with MP dose intolerance in Arab patients with ALL. Genotyping for additional polymorphisms may be warranted for potential gene/allele-dose effect.
- 31 August 2016
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 64 (1) , 146-150
NUDT15 and TPMT genetic polymorphisms are related to 6‐mercaptopurine intolerance in children treated for acute lymphoblastic leukemia at the Children's Cancer Center of Lebanon
Interindividual variability in thiopurine-related toxicity could not be completely explained by thiopurine S-methyltransferase (TPMT) polymorphisms, as a number of patients who are homozygous wild type or normal for TPMT still develop toxicity that necessitates 6-mercaptopurine (MP) dose reduction or protocol interruption. Recently, few studies reported on an inherited nucleoside diphosphate-linked moiety X motif 15 (NUDT15) c.415C>T low-function variant that is associated with decreased thiopurine metabolism and leukopenia in childhood acute lymphoblastic leukemia (ALL) and other diseases. The aim of this study is to measure the frequency of TPMT and NUDT15 polymorphisms and assess whether they are predictors of MP intolerance in children treated for ALL. One hundred thirty-seven patients with ALL of whom 121 were Lebanese were evaluated. MP dose intensity was calculated as the ratio of the tolerated MP dose to planned dose during continuation phase to maintain an absolute neutrophil count (ANC) dose above 300 per μl. One patient was NUDT15 heterozygous TC and tolerated only 33.33% of the planned MP dose, which was statistically significantly different from the median-tolerated MP dose intensity of the rest of the cohort (76.00%). Three patients had the TPMT*3A haplotype and tolerated 40.00–66.66% of the planned MP dose, which was also statistically significantly different from the rest of the cohort. This is the first report on the association of TPMT and NUDT15 polymorphisms with MP dose intolerance in Arab patients with ALL. Genotyping for additional polymorphisms may be warranted for potential gene/allele-dose effect.